newsfilter
← Latest News
GlobeNewswire·

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations for SCY-247 were accepted by the European